126 related articles for article (PubMed ID: 37037410)
21. Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase η.
Ouzon-Shubeita H; Baker M; Koag MC; Lee S
Biochem J; 2019 Feb; 476(4):747-758. PubMed ID: 30709915
[TBL] [Abstract][Full Text] [Related]
22. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.
Yang L; Shi T; Liu F; Ren C; Wang Z; Li Y; Tu X; Yang G; Cheng X
PLoS One; 2015; 10(3):e0120334. PubMed ID: 25781640
[TBL] [Abstract][Full Text] [Related]
23. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
[TBL] [Abstract][Full Text] [Related]
24. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Pang J; Ye L; Zhao D; Zhao D; Chen Q
Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
[TBL] [Abstract][Full Text] [Related]
25. Absence of REV3L promotes p53-regulated cancer cell metabolism in cisplatin-treated lung carcinoma cells.
Kong L; Murata MM; Digman MA
Biochem Biophys Res Commun; 2018 Jan; 496(1):199-204. PubMed ID: 29307819
[TBL] [Abstract][Full Text] [Related]
26. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant.
Halas A; Fijak-Moskal J; Kuberska R; Murcia Pienkowski V; Kaniak-Golik A; Pollak A; Poznanski J; Rydzanicz M; Bik-Multanowski M; Sledziewska-Gojska E; Płoski R
J Mol Med (Berl); 2021 Mar; 99(3):415-423. PubMed ID: 33474647
[TBL] [Abstract][Full Text] [Related]
27. Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer.
Sun X; Hou W; Liu X; Chai J; Guo H; Yu J
Cancer Cell Int; 2020 Dec; 20(1):580. PubMed ID: 33292253
[TBL] [Abstract][Full Text] [Related]
28. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
[TBL] [Abstract][Full Text] [Related]
29. DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents.
Sharma S; Shah NA; Joiner AM; Roberts KH; Canman CE
Mol Pharmacol; 2012 Jun; 81(6):778-87. PubMed ID: 22387291
[TBL] [Abstract][Full Text] [Related]
30. The vital role of polymerase ζ and REV1 in mutagenic, but not correct, DNA synthesis across benzo[a]pyrene-dG and recruitment of polymerase ζ by REV1 to replication-stalled site.
Hashimoto K; Cho Y; Yang IY; Akagi J; Ohashi E; Tateishi S; de Wind N; Hanaoka F; Ohmori H; Moriya M
J Biol Chem; 2012 Mar; 287(12):9613-22. PubMed ID: 22303021
[TBL] [Abstract][Full Text] [Related]
31. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.
Haynes B; Saadat N; Myung B; Shekhar MP
Mutat Res Rev Mutat Res; 2015; 763():258-66. PubMed ID: 25795124
[TBL] [Abstract][Full Text] [Related]
32. Regulation of DNA damage tolerance in mammalian cells by post-translational modifications of PCNA.
Kanao R; Masutani C
Mutat Res; 2017 Oct; 803-805():82-88. PubMed ID: 28666590
[TBL] [Abstract][Full Text] [Related]
33. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.
Zhou Y; Wan G; Spizzo R; Ivan C; Mathur R; Hu X; Ye X; Lu J; Fan F; Xia L; Calin GA; Ellis LM; Lu X
Mol Oncol; 2014 Feb; 8(1):83-92. PubMed ID: 24145123
[TBL] [Abstract][Full Text] [Related]
34. The Polymerase Activity of Mammalian DNA Pol ζ Is Specifically Required for Cell and Embryonic Viability.
Lange SS; Tomida J; Boulware KS; Bhetawal S; Wood RD
PLoS Genet; 2016 Jan; 12(1):e1005759. PubMed ID: 26727495
[TBL] [Abstract][Full Text] [Related]
35. The roles of DNA polymerase ζ and the Y family DNA polymerases in promoting or preventing genome instability.
Sharma S; Helchowski CM; Canman CE
Mutat Res; 2013; 743-744():97-110. PubMed ID: 23195997
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of mutagenesis induced by DNA lesions: multiple factors affect mutations in translesion DNA synthesis.
Zhang H
Crit Rev Biochem Mol Biol; 2020 Jun; 55(3):219-251. PubMed ID: 32448001
[TBL] [Abstract][Full Text] [Related]
37. The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.
Wei W; Ma XD; Jiang GM; Shi B; Zhong W; Sun CL; Zhao L; Hou YJ; Wang H
Oncol Res; 2020 Sep; 28(4):423-438. PubMed ID: 32331534
[TBL] [Abstract][Full Text] [Related]
38. The identification of translesion DNA synthesis regulators: Inhibitors in the spotlight.
Bertolin AP; Mansilla SF; Gottifredi V
DNA Repair (Amst); 2015 Aug; 32():158-164. PubMed ID: 26002196
[TBL] [Abstract][Full Text] [Related]
39. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
40. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
